Broncus Holding Corporation

Broncus Medical was founded in 1998. Its first technology, Bronchial Thermoplasty to treat asthma, was acquired by Boston Scientific at 440 million US dollars. Broncus has invested more than 150 million US dollars in product research and development and got more than 80 patents around the world. Its second generation core technology, virtual bronchoscopy navigation, was acquired by a Chinese venture capital group led by DiNova in 2012 and Broncus China was founded in the same year. Broncus now has a top international management and research team. It focuses on early diagnosis and treatment of respiratory diseases. Current research projects include minimum-invasive biopsy, navigation system, lung lesion marker for surgery and interventional therapy tools and accessories for lung nodules. 

Broncus China’s minimum-invasive and accurate lung cancer treatment project was awarded “the Best Growth Potential Project” in Shanghai Innovation and Entrepreneurship Competition 2015. In the Shanghai Innovation and Entrepreneurship Exhibition, Mr. Yang Xiong, deputy mayor of Shanghai, visited Broncus’ booth and gave Shanghai government’s support to Broncus projects. And Broncus’ joint research project with Shanghai Chest Hospital on early diagnosis and treatment of lung cancer has won the support of RMB 600,000 from Shanghai Science and Technology Commission’s innovation fund. Now Broncus China, as a leader in China market, has established a sales network covering whole China with Beijing, Shanghai and Guangzhou as key markets and a strong tram of sales and distributors. And its products have been sold all over the world. The mission of Broncus is to conquer lung cancer by revolutionizing diagnosis and treatment of lung cancer.